All In Biotech

Drug Trial Radar · NCT03780725

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 754111 in Patients With Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma Treated With BI 754111 in Combination With BI 754091

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

8

Actual

Start

Jan 22, 2019

Primary completion

Feb 19, 2020

Study completion Dec 8, 2020

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to determine the biodistribution and intra-tumor accumulation of \[89Zr\]Zr-BI 754111 at baseline and its change upon treatment

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Head and Neck Neoplasms

Interventions

  • BI 754111Drug

    Solution for infusion

  • [89Zr]Zr-BI 754111Drug

    Solution for infusion

  • BI 754091Drug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Standard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 1Time frame: At 96 hours and 144 hours post-injection of [89Zr]Zr-BI 754111 in each cycle.
  2. Standard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 2Time frame: At 96 hours and 144 hours post-injection of [89Zr]Zr-BI 754111 in each cycle.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Amsterdam UMC Locatie VUMC

    Amsterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.